Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis

Abstract Background We examined the impact of bisphosphonates as adjuvant therapy on recurrence giant cell bone tumors and various tumor stages surgical techniques this effect. Following a thorough examination literature up to January 2022, 10 studies including 601 adults with were reported; 295 these subjects received following surgery, 306 served control group. To examine possibility lowering tumors, comparison between group was made. In order evaluate tumor, odds ratios (OR) 95% confidence intervals (CIs) determined. Additionally, dichotomous technique random or fixed-effect model used effects pertinent procedures. Results Patients who had significantly lower postoperative rates outcomes in all (OR 0.19; CI 0.12–0.31, p = 0.001), patients stage I–II 0.29; 0.11–0.76, 0.01), III 0.17; 0.07–0.42, < 0.001); post-intralesional curettage 0.18; 0.06–0.49, 0.001) compared control. Bisphosphonates participants after broad excision, but there no discernible difference two groups terms 0.66; 0.11–3.91, 0.65). Conclusions intralesional curettage, use may incidence outcomes, appreciable identified extensive resection. According observed relationship, using is advised likelihood that can happen bone.